Background
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel zoonotic virus that can lead to severe acute respiratory infection (SARI) and life-threatening multi-organ dysfunction. It was first isolated from a fatal case of pneumonia in Jeddah, Saudi Arabia in 2012 [
1,
2]. Since then, community-acquired cases and clusters in healthcare settings have been reported mainly in Saudi Arabia [
3,
4], but also other countries [
5]. By the end of March 2020, the World Health Organization (WHO) reported 2553 confirmed cases in 27 countries (84.3% of cases in Saudi Arabia) with a case fatality rate of 34.4% [
6]. MERS clinical presentation ranges from asymptomatic infection to rapidly progressive severe respiratory failure with multi-organ failure [
7,
8]. Symptoms usually manifest after an incubation period of 2–14 days, with fever, cough, and dyspnea [
7‐
9]. Admission to the intensive care unit (ICU) is frequently needed [
7,
8].
Most severe MERS cases have been reported in older adults with chronic comorbidities, including diabetes mellitus [
2,
7,
9‐
12]. One cohort study found that among 47 MERS patients, 68% had diabetes [
7]. A case-control study demonstrated that diabetes was associated with an increased risk of MERS with an adjusted odds ratio [OR] of 6.99 (95% confidence interval [CI], 1.89–25.86) [
11]. Diabetes has also been associated with increased mortality in MERS patients [
9,
13]. In animal studies, diabetes was associated with a dysregulated immune response resulting in more severe and prolonged lung pathology following MERS-CoV infection [
14].
Previous studies that evaluated diabetes in MERS had relatively small sample sizes, were mostly performed in single centers, and included a mix of critically and non-critically ill patients. We performed this study in a large cohort of critically ill patients with MERS, with the hypothesis that patients with diabetes and viral SARI would have a complicated course of illness and worse outcomes compared with patients with no diabetes. The objectives of this study are to describe the clinical presentation, management, and outcomes (including mortality and MERS-CoV RNA shedding) of the Middle East Respiratory Syndrome in critically ill patients with diabetes.
Methods
We followed the STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) guidelines in reporting this study.
Patients and settings
This is a retrospective cohort study of adult (≥ 14-year-old) patients with SARI due to MERS-CoV who were admitted to the ICUs of 14 referral hospitals in Saudi Arabia between September 2012 and January 2018. The study was approved by the Institutional Review Boards of all participating centers. The characterization of this cohort has already been published earlier [
15]. SARI was defined as an acute respiratory infection, with fever and cough onset within the preceding 10 days and clinical or radiologic lung involvement. The presence of MERS-CoV was detected by real-time reverse-transcriptase polymerase chain reaction assay (rRT-PCR) performed on nasopharyngeal swabs or sputum samples in non-intubated patients and tracheal aspirates or bronchoalveolar lavage in intubated patients as recommended by the Saudi Arabian Ministry of Health. Confirmatory laboratory testing required a positive PCR on at least two specific genomic targets (upE and ORF1a) or a single positive target (upE) with sequencing of a second target (RdRpSeq or NSeq). In patients with suspected MERS and negative rRT-PCR, testing was repeated at the discretion of the treating teams. For infection control purposes, follow-up respiratory samples were collected approximately 1–2 times per week in MERS-CoV positive patients [
16] to assess clearance of MERS-CoV RNA [
15].
Data collection
Data were collected using the standardized International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) tool [
17]. In this study, we included patients demographics, baseline characteristics, presenting symptoms, physiologic and laboratory parameters, and severity of illness on ICU admission assessed by the Sequential Organ Failure Assessment
(SOFA) score [
18]. We also described the management in the ICU, including the use of invasive and noninvasive ventilation, extracorporeal membrane oxygenation (ECMO), prone positioning, and selected medications.
The primary outcome was 90-day mortality. Other studied outcomes were mortality at 14 and 28 days and on ICU and hospital discharge and ICU and hospital length of stay (LOS). For patients who survived hospital discharge, the 90-day outcome was assessed by calling the patients. We also assessed the time to clearance of MERS-CoV RNA, which was defined as the time from the first performed rRT-PCR until the test was negative on two occasions, without a positive test afterward [
15].
Statistical analysis
In this study, patients were divided into two groups based on the history of preexisting diabetes mellitus, as reported by patients. We compared patients with diabetes to patients with no diabetes using the Student t-test or the Mann-Whitney U test for continuous variables based on normality assumption, and the chi-square test or Fisher’s exact test for categorical variables.
To examine the independent association of diabetes with 90-day mortality in MERS patients, we performed multivariable logistic regression analysis adjusting for certain variables selected based on their clinical relevance, excluding the ones which were in the exposure–causal pathway. The variables entered in the model were age, sex, asthma or chronic pulmonary disease, chronic neurological disease, immunosuppressant use before admission, body mass index (BMI), and SOFA score.
For the multivariable logistic regression analysis, 24% (84/350) of patients had missing data (BMI – 81/350, 23%, age – 2/350, 0.5%, and SOFA score – 3/350, 0.8%). Hence missing data were handled using the multiple imputation technique with 50 imputations. Two imputation methods were considered to support the imputation technique: (I) “Predictive mean matching” and (II) “Impute then Transform” approach. The data set had an arbitrary missing data pattern and it was assumed that the missing data were missing at random, such that the probability of a missing observation may depend on observed values but not on unobserved values. Predictive mean matching was used to impute missing values for these variables. For the imputation of BMI, we used the “impute then transform” approach instead of imputing BMI directly, such that we imputed the height and weight assuming the imputation model was oblivious of the relation between these two variables [
19]. We reported the results of multivariable regression analysis without imputation (Model I: Complete case analysis) and with imputation (Model II: Multiple imputation).
Kaplan-Meier curves for the time to MERS-CoV RNA clearance were constructed censoring by hospital discharge or at 90 days whichever occurred first. The log-rank test was used to compare the median survival time between the groups. In addition, Kaplan-Meier curves for survival were also plotted and were censored at 90 days; the log-rank test was used to compare the time to survival between the groups. All statistical tests were two-sided with significance set at α < 0.05. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC).
Discussion
Our study demonstrates that patients with diabetes constituted around half of the critically ill patients with MERS; MERS patients with diabetes presented with dyspnea and sputum production and were more likely to have respiratory failure requiring mechanical ventilation than those with no diabetes; and diabetes was an independent predictor of mortality in MERS. Viral shedding duration was similar in patients with diabetes and no diabetes.
Diabetes is a global health problem and leads to significant complications that increase the risk of morbidity and development of critical illness. Saudi Arabia is among the countries with high prevalence rates (> 30%) [
20]. This may partly explain the high prevalence of diabetes in our cohort of critically ill MERS patients. In a Korean cohort of 186 patients with confirmed MERS patients, diabetes was present in 18.8% [
9]. In our study, patients with diabetes presented with more severe respiratory symptoms and hypoxia, required mechanical ventilation more frequently, and were given nitric oxide as rescue therapy more often. They also required vasopressors more often. These patients were more likely to receive ribavirin and interferon (alpha or beta-1a) alone or in combination; these antivirals have not been associated with improved outcomes in MERS [
21]. Recently, the MIRACLE trial demonstrated a reduction in mortality with the combination of lopinavir-ritonavir and interferon beta-1b; but none of patients in this cohort had received this combination [
22].
Diabetes is associated with reduced neutrophil chemotaxis after stimulation [
23] and blunted inflammatory response to endotoxemia [
24]. These abnormalities are thought to be the reasons why diabetics have an increased risk of various infections [
25]. For viral infections, diabetes has been associated with increased risk for hospitalization after H1N1 infection [
26], ICU admission [
26], and death [
27]. Comorbidities, including diabetes, have been associated with increased mortality in MERS patients [
28]. In a small cohort from two hospitals in Saudi Arabia, diabetes was present in 10.5% of survivors and 70.0% of non-survivors (
p = 0.002) [
29]. A study that evaluated MERS cases during the Korean outbreak found that diabetes was a risk factor for mortality on multivariate analysis (OR, 2.47; 95% CI, 1.06–5.72) [
9]. Analysis of 1743 MERS cases found that patients with comorbidity (diabetes mellitus, cardiovascular disease, renal disease, or pulmonary disease) had higher mortality risk (adjusted hazard ratio, of 3.7; 95% CI, 2.6–5.7) [
13]. In Severe Acute Respiratory Syndrome (SARS), diabetes (OR, 3.0; 95% CI, 1.4–6.3) and fasting blood glucose ≥7.0 mmol/L (OR, 3.3; 95%, CI 1.4–7.7) were independent predictors of death [
30]. Studies on the association of diabetes with disease severity and outcome in COVID-19 have yielded mixed results [
31‐
36]. In a meta-analysis, the risk of severe COVID-19 was not significantly increased in patients with diabetes (OR, 2.07; 95% CI, 0.89–4.82) [
36]. Other studies found no association between diabetes and morality [
32,
35].
It remains unclear how diabetes may contribute to increased disease severity and mortality in people infected with MERS-CoV. In a mouse model of MERS-CoV infection, diabetic mice had a prolonged phase of severe disease and delayed recovery compared to non-diabetic mice [
14]. This was associated with delayed inflammation which lasted through 21 days after infection [
14]. Diabetic mice exhibited fewer inflammatory monocyte/macrophages and CD4+ T cells and lower levels of TNF-a, IL-6, and IL-12b [
14]. This may explain the findings of severe MERS in patients with diabetes.
Viral shedding was relatively prolonged in our MERS patients. However, the time to clearance of MERS-CoV RNA was similar in patients with diabetes and no diabetes. Prolonged shedding has been reported in MERS patients in other studies [
37], and has been associated with corticosteroid use [
38]. Corticosteroids were used more commonly in patients with diabetes in the current study.
The findings of this study should be interpreted in light of its strengths and weaknesses. The strengths include that it is the largest cohort of critically ill patients with MERS. The limitations are related to the nature of the database and include diabetes diagnosis by history and absence of data on glycemic measures, such as type of diabetes, hemoglobin A1c, glucose control during hospitalization, and prior or current diabetes medications. In addition, glucose levels in patients with no diabetes were elevated, suggesting that some patients had stress hyperglycemia or undiagnosed diabetes. This may affect the associations between diabetes and various outcomes. Given the high prevalence of diabetes in Saudi Arabia, the results of our study may not be generalizable to populations of lower diabetes prevalence.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.